Evaluating a New High-CBD Treatment for Gynecologic Pain from Endometriosis, Adenomyosis, or PID

What this Trial Is About

Researchers are studying the potential effects of a high-cannabidiol CBD sublingual product on gynecologic pain in individuals with endometriosis, adenomyosis, or chronic pelvic inflammatory disease PID. This clinical trial is double-blind, placebo-controlled, and focuses on understanding specific targets and mechanisms of a hemp-derived, full-spectrum, high-CBD product for managing these conditions. Participants will be randomly assigned to receive one of two doses of the high-CBD product or a placebo. The study involves self-administration of the assigned product three times daily for one week. A subset of participants may undergo additional pharmacokineticpharmacodynamic studies involving extended blood sampling and questionnaires to better understand the bodys response to the CBD product. During the study, participants will attend three visits including screening, baseline, and final visits. These visits include clinical interviews, medical screenings, urine and blood sample collections, questionnaires, and sensory testing. Researchers will measure levels of CBD and its metabolites, inflammatory markers, and circulating anandamide at the start and end of the study. Participants will track their product use and may receive additional compensation if participating in extended procedures. The study aims to assess treatment effects over the 7-day period.

Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain